Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Cymycin - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Cymycin

Approved

STANDARD

Cymycin

Macter International Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 6cfb322df4d85d61
Company: Macter International Ltd.
Type: Standard

Approval Details

Approval Id: 6cfb322df4d85d61
Drug Approval Philippines Name: Cymycin
Product Name: Cymycin
Registration Number: DRP-7682-02
Brand Name: Cymycin
Generic Name: Clarithromycin
Dosage Form: Powder For Suspension (Oral Drops)
Dosage Strength: 125 mg/5mL
Manufacturer: Macter International Ltd.
Importer: Sahar International Trading, Inc.
Distributor: Ellebasy Medicale Trading
Issuance Date: 26 April 2021
Expiry Date: 23 February 2026
Pharmacologic Category: Antibacterial (Macrolides)
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

6cfb322df4d85d61

Type

Standard

Back to Philippines FDA Approvals